Revolutionizing Cancer Medicines: TCR bispecifics
Committed to Fighting for Cancer Patients
At IO:GULF we are committed to delivering the very best technology to our patients. Our TCR bispecific medicines approach is a proven technology representing the cutting edge of precision immune cancer medicines research and treatment.
TCR bispecific medication is already licensed in the USA and Europe and is making a real difference to the lives of cancer patients.
How do TCR bispecifics work?
These revolutionary drugs work by forming a bridge between the white blood cells (T cells) of the body's immune system and cancer cells. The creation of this bridge activates the immune system against the cancer cell and destroys it.
TCR Benefits
Because TCR bispecifics only bind to cancer cells and leave healthy tissue untouched, they are a breakthrough in patient safety when compared to current cancer therapies. With very few toxic side effects and the ability to work on a vast new array of previously untouchable cancer targets, TCR bispecifics represent a substantial leap forward in the fight against cancer.
